Business Context and Reporting Period
This Form 8-K is filed by Kindly MD, Inc. (not Nakamoto Inc., as referenced in the request metadata) for the reporting period ending May 12, 2025. The filing discloses executive compensation adjustments and a significant warrant exercise event. The company is an emerging growth company with common stock (KDLY) and warrants (KDLYW) listed on The Nasdaq Stock Market LLC.
Key Financial Metrics and Transactions
- Cash Inflow: The company received $4,219,584.33 from the exercise of warrants.
- Share Issuance: 730,923 shares of common stock were issued pursuant to warrant exercises between May 12, 2025, and May 15, 2025.
- Executive Equity Grants:
- Tim Pickett (CEO): 7,479 stock options (vesting Sept 1, 2025) and 28,780 fully vested restricted shares.
- Jared Barrera (CFO): 35,000 stock options (vesting over 9 months).
- Adam Cox (COO): 40,000 stock options (vesting over 9 months).
- Director Equity Grants: Amy Powell, Christian Robinson, and Gary Seelhorst each received 1,838 fully vested restricted shares, 538 fully vested options, and 2,000 options vesting upon a change of control.
Note: The filing does not provide data on revenue, net profit, operating margins, total debt, or liquidity ratios beyond the specific warrant proceeds mentioned above.
Material Changes and Unusual Items
The primary material change involves the modification of executive and director compensation agreements. Key unusual items include:
- Waiver of Future Equity: Executives and directors waived their rights to future equity in the Company, Nakamoto Holdings, Inc., or their subsidiaries/affiliates.
- Accelerated Vesting: Significant portions of the new grants (restricted stock and some options) are fully vested upon issuance.
- Warrant Exercise: A concentrated issuance of over 730,000 shares occurred within a three-day window, generating over $4.2 million in cash.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, revenue outlook, or management commentary regarding future financial performance. The primary risk disclosed relates to the dilution of existing shareholders due to the issuance of 730,923 new shares and the potential impact of the change-of-control provisions attached to director options.
Investor Verification Checklist
- Verify the relationship between Kindly MD, Inc. and Nakamoto Holdings, Inc. given the specific waiver of future equity rights in that entity.
- Confirm the impact of the 730,923 new shares on total outstanding share count and earnings per share (EPS) dilution.
- Review the exercise price of the warrants to understand the implied valuation at the time of exercise.
- Assess the cash burn rate and liquidity position post-transaction, as the filing does not disclose total cash balances.